Do your Microsoft Excel spreadsheets pass FDA muster? Can they meet strict 21 CFR Part 11 standards? Would you like to learn a defined approach that can make your task simple and straightforward saving you both time and money? Order this hands-on learning experience led by a trusted spreadsheet validation expert. Training is critical for anyone in the drug or device industry who oversees or uses spreadsheets for data collection, data processing or data reporting.
It's every drug- and devicemaker’s worst nightmare — inspectors coming through your front door with the power to shut you down. They're highly trained … ruthlessly committed to spotting your tiniest flaws … and tough as nails. If only you could question investigators in detail … before an inspection. Maybe you'd learn what you need to do to pass. Would they tell you? The answer is yes.
Impax Laboratories can market generic versions of Genzyme’s kidney disease drugs Renvela and Renagel in 2014 under a settlement with the brand drugmaker. Genzyme has granted Impax a license to sell a generic version of Renvela (sevelamer carbonate) 800-mg tablets beginning March 16, 2014, Impax said Tuesday. Impax can also sell oral suspension versions of Renvela and Renagel (sevelamer hydrochloride) beginning Sept. 16, 2014. Drug Industry Daily